Contact

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 5 EP applications Markus Gruber has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after October 10, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12844715

PAZOPANIB FORMULATION

IPC classification:
A01N 43/40
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Limited
Applicant:
GlaxoSmithKline Intellectual Property Management Limited
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Stephanie Anne Learoyd, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13704029

METHOD OF TREATING CANCER

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13742819

PREDICTION OF TREATMENT RESPONSE TO JAK/STAT INHIBITOR

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14732022

PHARMACEUTICAL COMBINATIONS OF A PI3K INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT

IPC classification:
A61P 35/04, A61P 35/00, A61K 31/5377, A61K 31/4439, A61K 31/357
Applicant:
Novartis AG
Agent:
Markus Gruber, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP12742225

Combination of pazopanib and topotecan

IPC classification:
A61P 35/00, C07D 231/56, A61K 45/06, A61K 31/4745, A61K 31/506
Applicant:
GlaxoSmithKline Intellectual Property Limited
Applicant:
Novartis AG
Agent:
Stephanie Anne Learoyd, GlaxoSmithKline
Agent:
Markus Gruber, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED

Please Sign in to use this feature